With 2.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.58 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $63.08 whereas the lowest price it dropped to was $56.35. The 52-week range on RYTM shows that it touched its highest point at $68.58 and its lowest point at $35.17 during that stretch. It currently has a 1-year price target of $78.83. Beta for the stock currently stands at 2.21.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RYTM was up-trending over the past week, with a rise of 15.46%, but this was up by 18.88% over a month. Three-month performance dropped to -2.10% while six-month performance rose 16.32%. The stock gained 42.40% in the past year, while it has gained 3.13% so far this year. A look at the trailing 12-month EPS for RYTM yields -4.36 with Next year EPS estimates of -1.39. For the next quarter, that number is -0.69. This implies an EPS growth rate of 40.74% for this year and 46.04% for next year.
Float and Shares Shorts:
At present, 62.39 million RYTM shares are outstanding with a float of 56.93 million shares on hand for trading. On 2025-03-14, short shares totaled 4.71 million, which was 744.99995 higher than short shares on 1739491200. In addition to Dr. David P. Meeker M.D. as the firm’s Chairman, President & CEO, Mr. Hunter C. Smith M.B.A. serves as its CFO & Treasurer.
Institutional Ownership:
Through their ownership of 1.07768 of RYTM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, RYTM reported revenue of $41830000.0 and operating income of -$41255000.0. The EBITDA in the recently reported quarter was -$37552000.0 and diluted EPS was -$0.72.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RYTM since 5 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RYTM analysts setting a high price target of 94.0 and a low target of 63.0, the average target price over the next 12 months is 78.83333. Based on these targets, RYTM could surge 62.83% to reach the target high and rise by 9.13% to reach the target low. Reaching the average price target will result in a growth of 36.56% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$4.01297 being high and -$4.61192 being low. For RYTM, this leads to a yearly average estimate of -$4.32243. Based on analyst estimates, the high estimate for the next quarter is -$0.47 and the low estimate is -$0.73. The average estimate for the next quarter is thus -$0.61.
